NVNathalie Vermeulen

Nathalie Vermeulen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Recognitions

Top Cited Scholar (2024,2025)

Nathalie Vermeulen has a total of 447 co-authors. Here are the top co-authors by number of shared publications:

  • Carla Tomassetti

    University Hospitals Leuven, Dept. Obstetrics and Gynaecology (Tomassetti), Leuven University Fertility Center, Belgium; KU Leuven, Faculty of Medicine, Dept. Development and Regeneration (Tomassetti), LEERM (Lab of Endometrium, Endometriosis and Reproductive Medicine), Belgium

    8 shared publications
  • Severine Vermeire

    Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

    7 shared publications
  • Grigoris Grimbizis

    1st Dept Obstet Gynecol, Medical School (Grimbizis), Aristotle University of Thessaloniki, Thessaloniki, Greece

    6 shared publications
  • Kersti Lundin

    Dept of Obstetrics and Gynecology, The Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    6 shared publications
  • Rudy Leon De Wilde

    University Hospital for Gynecology, Pius Hospital, University Medicine Oldenburg, Oldenburg, Germany

    6 shared publications
  • Stacey Missmer

    Department of Obstetrics, Gynecology and Reproductive Biology (Missmer), Michigan State University College of Human Medicine, East Lansing, MI, USA; Department of Epidemiology (Missmer), Harvard University T H Chan School of Public Health, Boston, MA, USA; World Endometriosis Research Foundation (Missmer), WERF, London, UK

    6 shared publications

Latest Publications

  • Open Access

    ESHRE position paper: international limits on the number of offspring per gamete donor

    by Lucy Frith, Johanna Tassot, Aisling Ahlstrom, Dinka Pavičić Baldani, Carlos Calhaz-Jorge, Gueorgui Nikolov, Petra Thorn, Nathalie Vermeulen, Jackson Kirkman-Brown

    STUDY QUESTION: How should the number of offspring per gamete donor be regulated at an international level? SUMMARY ANSWER: The European Society of Human Reproduction and Embryology (ESHRE) recommends introducing a European Union (EU)-wide limit on the number of families per gamete donor, starting at 50 families and gradually reducing it to a maximum of 15 families or lower, supported by an EU-wide donor registry to monitor compliance. WHAT IS KNOWN ALREADY: Most European countries impose national limits on the number of offspring or families per donor, but these limits vary widely and are not always enforced. Cross-border movement of patients and the export of donor gametes between countries mean that large donor sibling groups can still emerge despite these restrictions. What matters to donor-conceived people is the total number of donor siblings, regardless of which country they are in, making a transnational limit the only relevant mechanism that can address this issue. STUDY DESIGN, SIZE, DURATION: This position paper sets out principles relevant to international donor offspring limits and the position and policy recommendations of ESHRE, focusing on the EU level. PARTICIPANTS/MATERIALS, SETTING, METHODS: This ESHRE position paper was developed by a multidisciplinary expert working group. Recommendations are supported by data from the literature, where available. The first version was published for stakeholder review in November 2025, with 45 completed review forms received from organizations representing donor-conceived people, families built through donor conception and infertility patients, national fertility societies, researchers, professionals from different disciplines, and gamete banks. The paper was then revised on the basis of the stakeholder review. MAIN RESULTS AND THE ROLE OF CHANCE: ESHRE considers that the wellbeing of donor-conceived people should have the highest priority when determining limits, while also balancing the wellbeing of prospective parents. Limits should be set for the number of families rather than individual children. ESHRE proposes a phased introduction starting at 50 families per donor, being reduced to a maximum of 15 families or lower, alongside a 20-year cap on distributing gametes to new families after the first donation. National limits should still be upheld where they are lower, and donors should be able to set their own lower personal limit. Compliance should be monitored through an EU-wide donor registry or, failing that, national registries, with gamete banks (including non-EU banks exporting into the EU) obliged to enforce the limit, donors required to declare all previous donations, and families counted as potential live births unless confirmed otherwise. LIMITATIONS, REASONS FOR CAUTION: The evidence base on the psychosocial impact of large donor sibling groups is small and developing, and definitive evidence of harm is limited. Research on the preferences of donor-conceived people, donors, and recipients regarding offspring limits is scarce and inconclusive. These recommendations therefore take a precautionary approach, and the proposed 15-family limit should be reviewed in light of developing knowledge during the transition period. WIDER IMPLICATIONS OF THE FINDINGS: An EU-wide limit would represent a feasible first step towards an international limit. An EU-wide donor registry could potentially serve secondary purposes such as supporting tracing in case of the diagnosis of a serious genetic condition and giving access to information to donors and donor-conceived people. FUNDING: Support for the working group was provided by ESHRE. DISCLOSURES: L.F. and C.C.-J. report travel support from ESHRE. D.P.B. reports speakers' fees from Merck, Ferring, Gedeon Richter and MSD, travel support from ESHRE, and a position as the president of the Croatian Society for Gynaecological Endocrinology and Human Reproduction. A.A. reports speakers’ fees from Merck Healthcare KGaA and Ferring, travel support from ESHRE, passive shareholder interest in Inception Midco 1. S.à r.l., membership in a subgroup of the European Medical Devices Coordination Group, and a position as vice chair of the EXPAMED panel on obstetrics, gynaecology and reproductive medicine. G.N. reports speakers’ fees from Gedeon-Richter and Organon, travel support from ESHRE, and a position as past chairman and member of the Executive Committee of the Bulgarian Association for Human Reproductive Embryology. P.T. reports speakers’ fees and travel support from Ferring and Gedeon Richter and a position as a board member on the Arbeitskreis donogene Insemination. J.K.-B. reports speakers’ fees from Ferring, IBSA, Merck and CooperSurgical, travel support from Merck and ESHRE, an associate editor position for the journal Andrology, and a position as chair of the scientific advisory committee of the Association for Reproductive and Clinical Scientists (ARCS). The remaining authors (J.T. and N.V.) have nothing to declare. TRIAL REGISTRATION NUMBER: n/a.


  • Open Access

    ESHRE’s key research priorities in infertility: maximizing impact on science, people and society

    by Johanna Tassot, Aisling Ahlstrom, Antonio Capalbo, Ying Cheong, Giovanni Coticchio, Ilse Delbaere, Christina Fadler, Sofia Gameiro, Mariëtte Goddijn, Jackson Kirkman-Brown, et al.

    STUDY QUESTION: Which research topics in the area of infertility should be prioritized in the allocation of research resources? SUMMARY ANSWER: Twelve research priorities were formulated, spanning the following areas: preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments, optimizing psychosocial support and deepening knowledge on preimplantation development and early pregnancy. WHAT IS KNOWN ALREADY: Many research gaps related to infertility and its management remain understudied and underfunded, making it important to set priorities to ensure appropriate allocation of research resources. STUDY DESIGN, SIZE, DURATION: The European Society of Human Reproduction and Embryology (ESHRE) appointed a multidisciplinary working group, including a patient representative, to develop a list of research priorities related to infertility, which are relevant to researchers and institutions that fund research. PARTICIPANTS/MATERIALS, SETTING, METHODS: A list of research topics was collated based on the recommendations for future research formulated in ESHRE’s evidence-based guidelines and suggestions submitted by ESHRE’s Special Interest Groups as call topics for the ESHRE research grants. A scoring tool was developed to assess the expected impact of research on each topic on individuals, society and scientific advancement. Topics were scored independently by the working group members and the 12 topics with the highest scores were selected for presentation in this paper. MAIN RESULTS AND THE ROLE OF CHANCE: Using our newly developed scoring tool, we have identified 12 research priorities that broadly fall under six areas. These are preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments (two priorities per area selected), optimizing psychosocial support (one priority selected) and deepening knowledge on preimplantation development and early pregnancy (three priorities selected). LIMITATIONS, REASONS FOR CAUTION: The impact scoring tool would benefit from further testing and refinement in future projects. The scoring of some impact indicators is heavily based on the judgment and expertise of the scorers, which was accounted for by ensuring representation of knowledge and experience from all relevant disciplines and subject areas as well as the patient perspective within the working group. WIDER IMPLICATIONS OF THE FINDINGS: This paper may serve to stimulate further thought and discussion within the infertility research community on the potential impact of proposed and ongoing research. It will furthermore inform and encourage policy makers involved in research funding allocation and contribute to a more efficient and purposeful allocation of research resources towards infertility research. STUDY FUNDING/COMPETING INTEREST(S): The technical support for this project was provided by ESHRE. A.C. reports employment at Juno Genetics. Y.C. reports a grant from Guerbet and honoraria from Ferring, Merck, Abbot, Nordic Pharma and Organon. G.C. reports consulting fees from Gedeon Richter and honoraria from Cooper Surgical. S.G. reports the development of www.myjourney.pt licensed under a CC BY-NC-SA 4.0 licence. J.K.-B. reports grants from the NIHR Evaluation and Studies Coordinating Centre, the Gates Foundation, the Economic and Social Research Council, BAYER Consumer Health and MRC Confidence in Concept; honoraria from Ferring and Cooper Surgical; travel support from Ferring, Cooper Surgical, Congressworks LLP, Deutsche Gesellschaft für Andrologie e. V., BAYER, University of Munster and ESHRE; a patent for microchannel sperm cell preparation; and a leadership or fiduciary role in the Association of Clinical and Reproductive Scientists. A.P. reports grants (to her institution) and consulting fees from Gedeon Richter, Ferring, Merck A/S and Cryos; honoraria from Gedeon Richter, Ferring, Merck A/S and Organon; and travel support (to her institution) from Gedeon Richter. H.S.N. reports grants from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond and the Independent Research Fund Denmark; speaker’s fees from Ferring, Merck A/S, Astra Zeneca, Cook Medical, Gedeon Richter, Ibsa Nordic, Novo Nordisk A/S; co-development of an app with the Maternity Foundation; and co-founding a project with Lulu Health. The remaining authors (J.T., A.A., I.D., C.F., M.G., A.S.L., M.M.-R., V.N., A.O., N.R., M.S.-L., P.T., N.V., S.V. and K.S.) have nothing to declare. TRIAL REGISTRATION NUMBER: N/A


  • Open Access

    Complementary therapies for women with premature ovarian insufficiency: a systematic literature review to inform the 2024 update of the ESHRE/ASRM/IMS/CRE-WHiRL guidelines on premature ovarian insufficiency

    by Alison Maunder, Nathalie Vermeulen, Amanda J. Vincent, Nick Panay, Carolyn Ee

    Premature ovarian insufficiency (POI) is associated with reduced quality of life and increased health risks. While hormone therapy (HT) is standard treatment, some women seek other options to treat its sequelae. This review explores the role of complementary therapies for POI. A systematic search of four databases up to January 2024 identified randomized controlled trials, systematic reviews, meta-analyses and umbrella reviews that examined the use of complementary therapies by women with POI. Outcomes included menopausal symptoms, gonadotropins, antral follicle count, ovarian volume and quality of life. Study quality was evaluated using Cochrane Risk of Bias and A MeaSurement Tool to Assess systematic Reviews (AMSTAR 2). The search identified 1869 citations, with nine studies meeting the inclusion criteria. Findings suggest that Chinese herbal medicine and acupuncture may alleviate menopausal symptoms and regulate gonadotropins in women with POI, although evidence is very limited. There is insufficient evidence for other complementary therapies for POI. While Chinese herbal medicine may improve menopausal symptoms, there is insufficient evidence specific to POI. There is a clear need for additional and rigorous research on the efficacy and safety of complementary therapies for POI. Evidence does not support complementary medicines as replacements for HT.


  • Open Access

    To err is human, also in medically assisted reproduction: a cross-sectional study on error management practices

    by Alessandra Alteri, Kelly Tilleman, Nathalie Vermeulen, Giuliana Baccino, Kenny A Rodriguez-Wallberg, Arianna D’aNgelo, Theofano Bounartzi, Zdravka Veleva, Heidi Mertes

    STUDY QUESTION: How do medically assisted reproduction (MAR) centres manage errors, and what are the practices for reporting adverse incidents and non-conformities to National Competent Authorities (NCA) and disclosing them to patients? SUMMARY ANSWER: The study reveals a diverse landscape of error management practices in MAR centres, with varying approaches to reporting and disclosure, emphasizing a mix of transparency and systematic management of non-conformities. WHAT IS KNOWN ALREADY: Previous studies have highlighted the critical nature of error management in MAR settings which are inherently susceptible to errors due to their complexity. Despite this recognition, comprehensive data on error management practices across different MAR centres have been limited. STUDY DESIGN, SIZE, DURATION: A cross-sectional study was set up to gather data on the current practice with regards to error management at MAR centres. Data were collected between 25 April and 25 May 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: An online survey was designed, using the online SurveyMonkey tool, to consist of 17 questions concerning three domains: error management in the MAR centre, reporting to NCA and disclosure of non-conformities to patients. The survey was distributed to professionals working in MAR centres through the ESHRE membership mailing list. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 464 replies were received and following exclusion of invalid results, the final dataset included the replies of 387 respondents. A majority, ∼71.6% of respondents, confirmed that both laboratory and clinical non-conformities are systematically recorded, predominantly using digital platforms. Mainly, all types of errors are recorded based on their severity, including near-misses. In terms of discussing incidents, about 85.8% of the centres reported that they regularly hold meetings to review them. However, practices varied considerably when it came to reporting non-conformities to the NCA and disclosing them to patients. Only 15.1% of respondents reported all types of incidents (major, moderate, and significant) to the NCA, while a significant portion, 65.6%, indicated that they report only major incidents. Concerning disclosure practices to patients, a majority (52%) stated that their centres always communicate incidents to patients, indicating a trend towards transparency in patient care. However, 11.7% of respondents mentioned that they do not disclose to patients, highlighting a gap in proactive patient communication in some centres. LIMITATIONS, REASONS FOR CAUTION: The study’s sample may not be representative of all MAR centres, with a potential bias towards practices in countries with higher respondent rates (Spain, UK, Italy); also the possibility of having received multiple responses from the same centre could not be ruled out. Additionally, despite survey anonymity, there may be a tendency for respondents to provide socially desirable answers. WIDER IMPLICATIONS OF THE FINDINGS: These findings contribute to a broader understanding of error management in MAR centres worldwide, highlighting the need for standardized reporting systems and more transparent communication with patients. This study also underscores the importance of fostering a culture of safety and continuous learning from non-conformities in the MAR sector. STUDY FUNDING/COMPETING INTEREST(S): K.T. disclosed support for attending meetings and/or travel from Ferring, Cooper Surgical, Fujifilm, and Vitrolife group. K.R.-W. disclosed support from Radiumhemmets Forskningsfonder and The Swedish Cancer Society; grants from Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Fund, Radiumhemmets Forskningsfonder, Stockholm County Council FoU, Karolinska Institutet and IngaBritt och Arne Lundbergs Forskningsstiftelse; royalties; consulting fees from the Swedish Ministry of Health and Welfare; honoraria from Roche (for chairmanship and lectures), Pfizer (for chairmanship and lectures), Organon (lectures), and IBSA (Advisory Board for educational event); support for meetings and/or travel from Organon and Regionstockholm; participation at advisory boards for Merck and Ferring; receipt of equipment from Merck and Ferring. Z.V. disclosed research grants from ESHRE and Juhani Aaltonen Foundation; and support for meetings and/or travel from ESHRE. The other authors had no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.


  • The Istanbul Consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment† ‡

    by Giovanni Coticchio, Aisling Ahlström, Gemma Arroyo, Basak Balaban, Alison Campbell, Maria José De Los Santos, Thomas Ebner, David K. Gardner, Borut Kovačič, Kersti Lundin, et al.


  • Top Cited Papers
    Open Access

    The Istanbul consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment,

    by The Working Group on the update of the ESHRE/ALPHA Istanbul Consensus, Giovanni Coticchio, Aisling Ahlström, Gemma Arroyo, Basak Balaban, Alison Campbell, Maria José De Los Santos, Thomas Ebner, David K Gardner, Borut Kovačič, et al.

    STUDY QUESTION: What are the current recommended criteria for morphological assessment of oocytes, zygotes, and embryos? SUMMARY ANSWER: The present ESHRE/Alpha Scientists in Reproductive Medicine consensus document provides several novel recommendations to assess oocyte and embryo morphology and rank embryos for transfer. WHAT IS KNOWN ALREADY: A previous Alpha Scientists in Reproductive Medicine/ESHRE consensus on oocyte and embryo morphological assessment was published in 2011. After more than a decade, and the integration of time-lapse technology into embryo culture and assessment, a thorough review and update was needed. STUDY DESIGN, SIZE, DURATION: A working group consisting of Alpha Scientists in Reproductive Medicine executive committee members and ESHRE Special interest group of Embryology members formulated recommendations on oocyte and embryo assessment. PARTICIPANTS/MATERIALS, SETTING, METHODS: The working group included 17 internationally recognized experts with extensive experience in clinical embryology. Seven members represented Alpha Scientists in Reproductive Medicine and eight members represented ESHRE, along with to two methodological experts from the ESHRE central office. Based on a systematic literature search and discussion of existing evidence, the recommendations of the Istanbul Consensus (2011) were reassessed and, where appropriate, updated based on consensus within the working group. A stakeholder review was organized after the updated draft was finalized. The final version was approved by the working group, the Alpha executive committee and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: This updated consensus paper provides 20 recommendations focused on the timeline of preimplantation developmental events and morphological criteria for oocyte, zygote, and embryo assessment. Based on duration of embryo culture, recommendations are given on the frequency and timing of assessments to ensure consistency and effectiveness. LIMITATIONS, REASONS FOR CAUTION: Several criteria relevant to oocyte and embryo morphology have not been well studied, leading to either a recommendation against their use for grading or for their use in ranking rather than grading. Future updates may require further revision of these recommendations. WIDER IMPLICATIONS OF THE FINDINGS: This document provides embryologists with advice on best practices when assessing oocyte and embryo quality based on the most recent evidence. STUDY FUNDING/COMPETING INTEREST(S): The consensus meeting and writing of the paper were supported by funds from ESHRE and Alpha Scientists in Reproductive Medicine. The working group members did not receive any payment. G.C. declared payments or honoraria for lectures from Gedeon Richter and Cooper Surgical. A.C. declared text book royalties (Mastering Clinical Embryology, published 2024), consulting fees from Cooper Surgical, Gedeon Richter and TMRW Life Sciences, honoraria for lectures from Merck, Ferring, and Gedeon Richter, and participation in the HFEA Scientific Advances Committee; she also disclosed being treasurer and vice-president of Alpha Scientists in Reproductive Medicine, a shareholder in Care Fertility Limited and Fertile Mind Limited, and having stock options in TMRW Life Sciences and U-Ploid Biotechnology Ltd. L.R. declared consulting fees from Organon, payments or honoraria for lectures from Merck, Organon, IBSA, Finox, Geden Richter, Origio, Organon, Ferring, Fundation IVI; she also disclosed being a member of the Advisory Scientific Board of IVIRMA (Paid) and a member of the Advisory Scientific Board of Nterilizer (unpaid). I.S. declared payments or honoraria for lectures from Vitrolife and Cooper Surgical, and stock options from Alife Health. M.A. declared payments or honoraria for lectures from Vitrolife and support for attending meetings from Vitrolife and Cooper Surgical (both unrelated to this manuscript). The other authors have no conflicts of interest to declare. DISCLAIMER: This Good Practice Recommendations (GPRs) document represents the consensus views of the members of this working group based on the scientific evidence available at the time of the meeting. GPRs should be used for information and educational purposes. They should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care or be exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, or variations based on locality and facility type.


  • Premature ovarian insufficiency and the risk of breast cancer: author reply

    by Nick Panay, Nathalie Vermeulen, Richard A. Anderson, Amanda J. Vincent, on behalf of the POI guideline development group members

  • Premature ovarian insufficiency and the risk of breast cancer: author reply

    by Nick Panay, Nathalie Vermeulen, Richard A. Anderson, Amanda J. Vincent

  • Open Access

    Reply: Premature ovarian insufficiency and the risk of breast cancer

    by Nick Panay, Nathalie Vermeulen, Richard A Anderson, Amanda J Vincent


  • Open Access

    Ethical considerations on surrogacy

    by Writing Group on behalf of the ESHRE Ethics Committee, Francoise Shenfield, Basil Tarlatzis, Guiliana Baccino, Theofano Bounartzi, Lucy Frith, Guido Pennings, Veerle Provoost, Nathalie Vermeulen, Heidi Mertes

    Surrogacy is the assisted reproductive technology (ART) practice in which a person becomes pregnant, carries, and delivers a child on behalf of another couple/person, who are the intended parent(s). Surrogacy is an especially complex practice as the interests of the intended parents, the gestational carrier, and the future child may differ. This paper considers ethical questions related to different forms of surrogacy. It concludes that non-commercial surrogacy is an acceptable method of assisted reproduction for specific indications. When using surrogacy to form a family, it is essential that there are measures to protect all parties, to guarantee well-considered decision-making, and to minimize risks. The current paper formulates recommendations to promote these measures. This paper is an update to the ESHRE Task Force Ethics and Law Paper 10: Surrogacy and replaces this paper.